Source-grounded facts extracted from Tempest Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stella Xu resigned as Director at Tempest Therapeutics, Inc..
“On December 20, 2021, Stella Xu notified the board of directors (the “Board”) of Tempest Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Board, effective January 5, 2022.”
Nicholas Maestas was appointed as vice president, strategy and finance and principal financial officer at Tempest Therapeutics, Inc..
“On July 12, 2021, Nicholas Maestas, age 41, joined the Company as vice president, strategy and finance and is the Company’s principal financial officer.”
Ronit Simantov was appointed as Class III director at Tempest Therapeutics, Inc..
“Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board.”
Nicholas Maestas was appointed as vice president, strategy and finance and principal financial officer at Tempest Therapeutics, Inc..
“On July 12, 2021, Nicholas Maestas, age 41, joined Tempest Therapeutics, Inc. (the “Company”) as vice president, strategy and finance and is the Company’s principal financial officer.”
Christine Pellizzari was appointed as Class II Director at Tempest Therapeutics, Inc..
“On July 1, 2021, the Board appointed Christine Pellizzari as a Class II Director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.